Record mula sa primary source
Decision-gradeTopline na resulta
Ionis: bepirovirsen Phase 3 B-Well 1 & 2 topline positive sa CHB
Inihayag ang positibong topline results mula sa pivotal Phase 3 B-Well 1 at B-Well 2 studies ng bepirovirsen sa chronic hepatitis B. Ipinakita ng data ang statistically significant at clinically meaningful functional cure rate, na nag-trigger ng planned worldwide regulatory submissions sa 2026.
Mahahalagang fact
- Na-file
- Ene 12, 2026, 12:00 PM
- Kaganapan
- Topline na resulta
- Direksyon
- Positibo
- Kumpanya
IONSIonis- Asset
- bepirovirsen
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
Sipi mula sa source
EX-99.1 2 ef20062670_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Mahusay ang posisyon ng Ionis para sa patuloy na momentum at substantial value creation sa 2026 na may dalawang bagong independent launches at ilang pivotal data readouts - TRYNGOLZA ® (olezarsen) outperforms expectations, achieved 2025 preliminary U.S. net product sales of $105M* bilang unang FDA-approved treatment para sa FCS; sNDA para sa sHTG submitted for review – - Increasing annual TRYNGOLZA peak net sales guidance to >$2B para sa sHTG – - Positive topline results announced para sa pivotal Phase 3 program ng bepirovirsen sa chronic hepatitis B; first of five Phase 3 readouts mula sa partnered programs expected this year – CARLSBAD, Calif., January 12 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlight
Higit pa tungkol sa asset na ito
Materyal
Abr 28, 2026
06:06 AM
IONSIonis